| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Biowatch Alert: Repligen Jumps On Higher Volume, No News!
Posted on 04/09/2007 17:09:13 | Link | Post Comment
by H.S. Ayoub
BioHealthInvestor.com
Shares of Repligen Corporation (RGEN) gained almost 9% on Thursday as volume quadrupled the 3 month daily average.
There were no significant news releases or other significant events that could be detected.
Repligen develops novel therapeutics for the treatment of diseases of the central nervous system. It also sells Protein A products; which can be used for diagnostic purposes, including the detection of pancreatic disorders.
The company also conducts its own drug development programs for schizophrenia, bipolar disorder, and neurodegeneration.
The $104 million company has $19.5 million in cash and no debt according to the latest Yahoo! financial data. Yearly Revenue has been increasing for the last 3 years, and in fact, the company recorded its first yearly profit in 2006.
Shares of Repligen closed at $3.43, a little more than 20% away from the 52-week high of $4.17.
Repligen has made BHI's BioWatch Alert List.
Source: BioHealthInvestor.com
_____________________
BioHealthInvestor.com
Shares of Repligen Corporation (RGEN) gained almost 9% on Thursday as volume quadrupled the 3 month daily average.
There were no significant news releases or other significant events that could be detected.
Repligen develops novel therapeutics for the treatment of diseases of the central nervous system. It also sells Protein A products; which can be used for diagnostic purposes, including the detection of pancreatic disorders.
The company also conducts its own drug development programs for schizophrenia, bipolar disorder, and neurodegeneration.
The $104 million company has $19.5 million in cash and no debt according to the latest Yahoo! financial data. Yearly Revenue has been increasing for the last 3 years, and in fact, the company recorded its first yearly profit in 2006.
Shares of Repligen closed at $3.43, a little more than 20% away from the 52-week high of $4.17.
Repligen has made BHI's BioWatch Alert List.
Source: BioHealthInvestor.com
_____________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
Examples
Morpheus Trading - Thu Jul 17, 2008 01:15AM
NOTE: Please click on the charts below to enlarge them if th [read more]
NOTE: Please click on the charts below to enlarge them if th [read more]
Morpheus Trading - Tue Jul 15, 2008 08:25AM
NOTE: Please click on the charts below to enlarge them [read more]
NOTE: Please click on the charts below to enlarge them [read more]
Morpheus Trading - Mon Jul 14, 2008 02:18AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
<< My Home | TheMoneyBlogs Home